

Thomas J Semrad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6133181/publications.pdf>

Version: 2024-02-01

22
papers

513
citations

933264

10
h-index

713332

21
g-index

22
all docs

22
docs citations

22
times ranked

1029
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. <i>Journal of Neurosurgery</i> , 2007, 106, 601-608.	0.9	236
2	Fibroblast Growth Factor Signaling in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2012, 13, 90-95.	1.1	38
3	Geographic variation of racial/ethnic disparities in colorectal cancer testing among medicare enrollees. <i>Cancer</i> , 2011, 117, 1755-1763.	2.0	36
4	Pharmacodynamic separation of gemcitabine and erlotinib in locally advanced or metastatic pancreatic cancer: therapeutic and biomarker results. <i>International Journal of Clinical Oncology</i> , 2015, 20, 518-524.	1.0	26
5	Relevance of Platinum-Sensitivity Status in Relapsed/Refractory Extensive-Stage Small-Cell Lung Cancer in the Modern Era: A Patient-Level Analysis of Southwest Oncology Group Trials. <i>Journal of Thoracic Oncology</i> , 2015, 10, 110-115.	0.5	25
6	Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. <i>Cancer Treatment and Research Communications</i> , 2017, 10, 21-26.	0.7	17
7	Oxaliplatin-DNA Adducts as Predictive Biomarkers of FOLFOX Response in Colorectal Cancer: A Potential Treatment Optimization Strategy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1070-1079.	1.9	15
8	Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. <i>Therapeutic Advances in Medical Oncology</i> , 2011, 3, 95-100.	1.4	12
9	Phase I study of the combination of temsirolimus and pazopanib in advanced solid tumors. <i>Anti-Cancer Drugs</i> , 2013, 24, 636-640.	0.7	12
10	Initial Treatment Patterns in Younger Adult Patients with Differentiated Thyroid Cancer in California. <i>Thyroid</i> , 2015, 25, 509-513.	2.4	12
11	Mediating Effect of Postsurgical Chemotherapy on Presence of Dementia and Survival among Patients 65 and Older with Stage III Colon Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1558-1563.	1.1	12
12	Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview. <i>Methods in Molecular Biology</i> , 2018, 1765, 281-297.	0.4	12
13	Disease Control Rate at 8 Weeks Predicts Subsequent Survival in Platinum-Treated Extensive Stage Small-Cell Lung Cancer: Results From the Southwest Oncology Group (SWOG) Database. <i>Clinical Lung Cancer</i> , 2016, 17, 113-118.e2.	1.1	10
14	Integrating Chemotherapy into the Management of Oligometastatic Colorectal Cancer: Evidence-Based Approach Using Clinical Trial Findings. <i>Annals of Surgical Oncology</i> , 2015, 22, 855-862.	0.7	9
15	Are there disparities in the presentation, treatment and outcomes of patients diagnosed with medullary thyroid cancer? An analysis of 634 patients from the California Cancer Registry. <i>Gland Surgery</i> , 2016, 5, 398-404.	0.5	8
16	Predictors of Neck Reoperation and Mortality After Initial Total Thyroidectomy for Differentiated Thyroid Cancer. <i>Thyroid</i> , 2018, 28, 1143-1152.	2.4	7
17	Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 335-341.	1.1	7
18	Molecular testing to optimize therapeutic decision making in advanced colorectal cancer. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, S11-20.	0.6	7

#	ARTICLE	IF	CITATIONS
19	Influence of Socioeconomic Status on Incident Medical Conditions in Two-Year Survivors of Adolescent or Young Adult Differentiated Thyroid Cancer. <i>Journal of Adolescent and Young Adult Oncology</i> , 2021, 10, 521-533.	0.7	5
20	Phase II clinical trials on investigational drugs for the treatment of pancreatic cancers. <i>Expert Opinion on Investigational Drugs</i> , 2015, 24, 781-794.	1.9	4
21	Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors. <i>Investigational New Drugs</i> , 2012, 30, 2001-2007.	1.2	3
22	ASCO 2015 update on gastrointestinal cancer: Checkpoint inhibition, multimodality strategies and secondary prevention. <i>Surgical Oncology</i> , 2015, 24, 371-374.	0.8	0